Panmure Gordon reiterated their buy rating on shares of Hutchison China MediTech Limited (LON:HCM) in a report published on Wednesday. Panmure Gordon currently has a GBX 2,630 ($32.86) price target on the stock.

Separately, Beaufort Securities restated a buy rating on shares of Hutchison China MediTech Limited in a report on Tuesday, November 1st.

Shares of Hutchison China MediTech Limited (LON:HCM) traded up 0.78% during trading on Wednesday, hitting GBX 1935.00. 2,350 shares of the company’s stock were exchanged. The firm’s market capitalization is GBX 1.17 billion. Hutchison China MediTech Limited has a 1-year low of GBX 1,612.50 and a 1-year high of GBX 2,896.60. The stock’s 50 day moving average is GBX 1,855.74 and its 200 day moving average is GBX 1,854.17.

In other Hutchison China MediTech Limited news, insider Michael Howell sold 2,500 shares of the company’s stock in a transaction that occurred on Friday, October 28th. The shares were sold at an average price of GBX 1,860 ($23.24), for a total value of £46,500 ($58,095.95).

ILLEGAL ACTIVITY NOTICE: “Hutchison China MediTech Limited’s (HCM) Buy Rating Reaffirmed at Panmure Gordon” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2016/11/24/hutchison-china-meditech-limiteds-hcm-buy-rating-reaffirmed-at-panmure-gordon-2.html.

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Stock Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related stocks with our FREE daily email newsletter.